Preventive screening for cardiovascular and related diseases is evolving with updated coding guidelines, coverage rules, and diagnostic innovations. From Medicare’s Physician Fee Schedule to portable ...

HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced ...

About 70 percent of our genes provide the blueprint for biomolecules whose function is only now being discovered – non-coding RNAs. Instead of being translated into proteins, they seem to perform ...

Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in ...